Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Rahul D. Ballal sold 53,400 shares of the firm's stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $23.95, for a total transaction of $1,278,930.00. Following the completion of the transaction, the director now directly owns 22,341 shares in the company, valued at $535,066.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Enliven Therapeutics Price Performance
ELVN stock opened at $21.08 on Friday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The company's 50-day moving average price is $16.66 and its two-hundred day moving average price is $14.16.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.
Institutional Investors Weigh In On Enliven Therapeutics
😱 This phenomenon is smashing regular market gains
From MillPub | Ad
Thanks to a little-known “Pathfinder” trading phenomenon…
Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading.
At every single market open.
Click here to save your seat and join the next LIVE workshop!
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $157,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $66,000. Exchange Traded Concepts LLC grew its holdings in shares of Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock valued at $121,000 after purchasing an additional 2,208 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Enliven Therapeutics during the 1st quarter valued at approximately $143,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $140,000. 95.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Mizuho started coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued a "buy" rating and a $34.00 target price on the stock.
Check Out Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
